I'm guessing that it's SANS and TBI as the second and third...

I'm guessing that it's SANS and TBI as the second and third indications.

SANS is already funded last year - they just need to formalise the agreement with invex one would hope https://www.birmingham.ac.uk/news/2021/research-to-boost-astronaut-health-for-future-space-missions-1

And TBI needs some more leg work to identify the appropriate biomarker or endpoint before using a GLP-1 for mild TBI. Fortunately, Sinclair is the lead investigator on a trial looking at uncovering exactly this. https://www.birmingham.ac.uk/news/2022/civilians-and-military-take-part-in-study-to-improve-concussion-prognosis

If big pharma is smart and do their due diligence, they'll see past the short term valuation of IIH as first indication, and recognise the potential of Invex to leverage a single agent into a blockbuster drug with multiple broad indications around reducing brain pressure.